Leerink analyst David Risinger downgraded Regeneron to Market Perform from Outperform with a $1,077 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Judge’s denial of Regeneron motion against Amgen a ‘speedbump’, says BMO Capital
- RBC says Regeneron reaction to biosimilar court ruling ‘overdone’
- Regeneron, Sanofi announce CHMP adopts positive opinion for Dupixent
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
- JMP Securities healthcare analysts hold an analyst/industry conference call